Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) -pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial

被引：0
|
作者：
Larson, Timothy
Jotte, Robert M.
Abdelaziz, Ahmed Mohammed Fouad
Konduri, Kartik
Richards, Donald A.
Meshad, Michael W.
Nagaiah, Govardhanan
Spira, Alexander I.
Khandelwal, Pankaj
Lorber, Ilana
Kedem, Tal Hetzroni
Rozencweig, Marcel
Fields, Scott Z.
机构：
[1] Minnesota Oncol Hematol PA, Minneapolis, MN USA
[2] Rocky Mt Canc Ctr, Lone Tree, CO USA
[3] Arizona Oncol, Tucson, AZ USA
[4] Texas Oncol PA, Dallas, TX USA
[5] Texas Oncol Tyler, Tyler, TX USA
[6] Southern Canc Ctr, Daphne, AL USA
[7] Arizona Oncol, Goodyear, AZ USA
[8] Virginia Canc Specialists, Fairfax, VA USA
[9] Texas Oncol Odessa, Odessa, TX USA
[10] NeoTx Ltd, Rehovot, Israel
[11] NeoTX Therapeut, Rehovot, Israel
[12] NeoTX, Princeton, NJ USA
[13] NeoTX Therapeut, Boka Raton, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8615
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials
    Shepherd, F. A.
    Douillard, J.
    Fukuoka, M.
    Saijo, N.
    Kim, S.
    Cufer, T.
    Sellers, M. V.
    Armour, A. A.
    Kim, E. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
    Wang, Z.
    Han, X.
    Guo, J.
    Zhu, D.
    Zhang, X.
    Tang, X.
    Meng, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1400 - S1400
  • [23] Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients
    Onoi, Keisuke
    Yamada, Tadaaki
    Morimoto, Kenji
    Kawachi, Hayato
    Tsutsumi, Rei
    Takeda, Takayuki
    Okada, Asuka
    Tamiya, Nobuyo
    Chihara, Yusuke
    Shiotsu, Shinsuke
    Takemura, Yoshizumi
    Yamada, Takahiro
    Hasegawa, Isao
    Katayama, Yuki
    Iwasaku, Masahiro
    Tokuda, Shinsaku
    Takayama, Koichi
    TARGETED ONCOLOGY, 2024, 19 (03) : 411 - 421
  • [24] Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Ramalingam, S.
    Schreeder, M.
    Steis, R.
    Guidice, R.
    Marshland, T.
    Butler, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?
    Spieler, Benjamin Oren
    Lopes, Gilberto
    Dal Pra, Alan
    Diwanji, Tejan
    Yechieli, Raphael
    Freedman, Laura M.
    Mihaylov, Ivaylo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Rizvi, Naiyer A.
    Garon, Edward B.
    Patnaik, Amita
    Gandhi, Leena
    Leighl, Natasha B.
    Balmanoukian, Ani Sarkis
    Goldman, Jonathan Wade
    Eder, Joseph Paul
    Johnson, Elizabeth
    Blumenschein, George R.
    Gubens, Matthew A.
    Papadopoulos, Kyriakos P.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Niewood, Michelle
    Emancipator, Kenneth
    Dolled-Filhart, Marisa
    Hanson, Mary Elizabeth
    Hui, Rina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Balmanoukian, A. S.
    Rizvi, N. A.
    Garon, E. B.
    Patnaik, A.
    Gandhi, L.
    Leighl, N. B.
    Goldman, J. W.
    Eder, J. P.
    Johnson, E. A.
    Blumenschein, G. R.
    Gubens, M. A.
    Papadopoulos, K. P.
    Lubiniecki, G. M.
    Zhang, J.
    Niewood, M.
    Emancipator, K.
    Dolled-Filhart, M.
    Hanson, M. E.
    Hui, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S1 - S2
  • [28] Combination therapy with ZD1839 ('Iressa') and docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): preliminary safety results of an open-label, pilot trial
    Manegold, C
    Gatzemeier, U
    Averbuch, S
    Fandi, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S55 - S55
  • [29] A phase Ib/II study of second-line cadonilimab, anlotinib and docetaxel in patients with checkpoint inhibitor (CPI)experienced advanced non-small cell lung cancer
    Han, B.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1646 - S1646
  • [30] Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC)
    Besse, B.
    Shaw, A. T.
    Solomon, B. J.
    Bauer, T. M.
    Chiari, R.
    Lin, C-C.
    Satouchi, M.
    Clancy, J. S.
    James, L. P.
    Abbattista, A.
    Felip Font, E.
    ANNALS OF ONCOLOGY, 2017, 28
12345